★ WIDE MOAT STOCKS & COMPETITIVE ADVANTAGES ★
VOL. XCIV, NO. 247
Stock Profile
AstraZeneca PLC (AZN) Moat Analysis
AstraZeneca PLC
AZN · London Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Request update
Spot something outdated? Send a quick note and source so we can refresh this profile.
Overview
AstraZeneca PLC is a global biopharmaceutical company with major therapy-area franchises in Oncology, CVRM, Respiratory & Immunology, Rare Disease, and Infectious Disease. The evidence-backed company-specific moat is patent and related exclusivity protection around marketed medicines; the costly clinical and regulatory process is an industry-wide barrier and is not counted separately. Pricing power is typically strongest for differentiated, protected specialty medicines, notably Oncology and Rare Disease, and weaker where payer leverage and generic competition are more pronounced. Infectious Disease and mature Other Medicines do not have a separately demonstrated moat in current disclosures. Patent challenges, biosimilar or generic entry, and global cost containment continually test durability.
Primary segment
Oncology
Market structure
Oligopoly
Market share
—
HHI: —
Coverage
6 segments · 6 tags
Updated 2026-07-11
Segments
Oncology
Innovator oncology therapeutics (branded prescription medicines)
Revenue
44.5%
Structure
Oligopoly
Pricing
strong
Share
—
Peers
Cardiovascular, Renal and Metabolism (CVRM)
CVRM therapeutics (diabetes, CKD, heart failure, cardiovascular and metabolic diseases)
Revenue
21.7%
Structure
Competitive
Pricing
moderate
Share
—
Peers
Respiratory & Immunology (R&I)
Respiratory and immunology therapeutics (asthma/COPD, immunology and inflammation)
Revenue
15.2%
Structure
Oligopoly
Pricing
moderate
Share
—
Peers
Infectious Disease
Infectious disease therapeutics and prophylaxis, including vaccines and immune therapies
Revenue
1.2%
Structure
Oligopoly
Pricing
weak
Share
—
Peers
Rare Disease
Rare disease therapeutics (specialty/orphan indications, often biologics)
Revenue
15.8%
Structure
Oligopoly
Pricing
strong
Share
—
Peers
Other Medicines
Mature branded medicines outside core therapy areas (often facing generic competition)
Revenue
1.7%
Structure
Competitive
Pricing
weak
Share
—
Peers
Moat Claims
Oncology
Innovator oncology therapeutics (branded prescription medicines)
Revenue share based on AstraZeneca Q1 2026 Total Revenue by Therapy Area: Oncology $6,798m / Total Revenue $15,288m.
IP Choke Point
Legal
IP Choke Point
Strength
Durability
Confidence
Evidence
Patents and related IP/exclusivity protect key oncology assets; loss in patent challenges or policy-driven erosion can accelerate generic/biosimilar competition and compress returns.
IP Choke Point moat: definition, examples, and stocks
Erosion risks
- Patent litigation losses or settlements
- Biosimilar entry after loss of exclusivity
- Regulatory/policy actions weakening IP protections
Leading indicators
- Patent challenge outcomes and injunctions
- Biosimilar applications/approvals in major markets
- Policy changes affecting patent/exclusivity regimes
Counterarguments
- IP can be challenged, narrowed, or designed around
- Fast followers can capture share quickly at LOE
Cardiovascular, Renal and Metabolism (CVRM)
CVRM therapeutics (diabetes, CKD, heart failure, cardiovascular and metabolic diseases)
Revenue share based on AstraZeneca Q1 2026 Total Revenue by Therapy Area: Cardiovascular, Renal & Metabolism $3,317m / Total Revenue $15,288m.
IP Choke Point
Legal
IP Choke Point
Strength
Durability
Confidence
Evidence
Patent/exclusivity on key CVRM brands supports returns while in-force; durability is medium given class competition and eventual LOE/genericization in large-volume categories.
IP Choke Point moat: definition, examples, and stocks
Erosion risks
- Patent challenges and earlier-than-expected generic entry
- Reference pricing and reimbursement tightening
- Class-level competition reducing effective pricing
Leading indicators
- Patent litigation docket and outcomes
- Generic filings/approvals in major markets
- Net-to-gross and rebate trends
Counterarguments
- Competitors can win share via outcomes evidence and payer contracting
- Large markets attract aggressive generic/biosimilar entry post-LOE
Respiratory & Immunology (R&I)
Respiratory and immunology therapeutics (asthma/COPD, immunology and inflammation)
Revenue share based on AstraZeneca Q1 2026 Total Revenue by Therapy Area: Respiratory & Immunology $2,318m / Total Revenue $15,288m.
IP Choke Point
Legal
IP Choke Point
Strength
Durability
Confidence
Evidence
Patents and exclusivity protect newer R&I brands, but effective durability is limited by payer leverage and eventual generic/biosimilar entry in large chronic categories.
IP Choke Point moat: definition, examples, and stocks
Erosion risks
- Biosimilar entry for biologics
- Patent invalidation or narrow claim construction
- Inhaled therapy commoditization
Leading indicators
- Biosimilar pipeline activity and approvals
- Patent challenge outcomes
- Net price and volume mix trends
Counterarguments
- Competitors can match mechanisms within a few years
- Payers can force rapid switching to preferred alternatives
Infectious Disease
Infectious disease therapeutics and prophylaxis, including vaccines and immune therapies
Revenue share based on AstraZeneca Q1 2026 Total Revenue by Therapy Area: Infectious Disease $182m / Total Revenue $15,288m. This segment was previously described as Vaccines & Immune Therapies in the record.
Insufficient segment-specific evidence to assign a moat claim.
Rare Disease
Rare disease therapeutics (specialty/orphan indications, often biologics)
Revenue share based on AstraZeneca Q1 2026 Total Revenue by Therapy Area: Rare Disease $2,420m / Total Revenue $15,288m.
IP Choke Point
Legal
IP Choke Point
Strength
Durability
Confidence
Evidence
IP protection and exclusivity are central to rare disease economics, but biosimilar competition can still emerge and materially impact revenue when protection weakens.
IP Choke Point moat: definition, examples, and stocks
Erosion risks
- Biosimilar erosion after LOE
- Patent challenges and earlier-than-expected entry
- Policy pressure to limit IP protections
Leading indicators
- Biosimilar approvals and tender outcomes
- Patient conversion dynamics within the franchise
- IP litigation outcomes in major markets
Counterarguments
- Biosimilars can scale quickly via hospital tender channels
- Switching can occur if payers mandate lower-cost alternatives
Other Medicines
Mature branded medicines outside core therapy areas (often facing generic competition)
Revenue share based on AstraZeneca Q1 2026 Total Revenue by Therapy Area: Other Medicines $253m / Total Revenue $15,288m.
Insufficient segment-specific evidence to assign a moat claim.
Evidence
A robust system for obtaining, maintaining and enforcing patents is a critical pillar of a sustainable innovation ecosystem.
The filing identifies enforceable patents as central to returns on long, costly and failure-prone drug development.
Risks & Indicators
Erosion risks
- Patent litigation losses or settlements
- Biosimilar entry after loss of exclusivity
- Regulatory/policy actions weakening IP protections
- Compulsory licensing in certain jurisdictions
- Patent challenges and earlier-than-expected generic entry
- Reference pricing and reimbursement tightening
Leading indicators
- Patent challenge outcomes and injunctions
- Biosimilar applications/approvals in major markets
- Policy changes affecting patent/exclusivity regimes
- Patent litigation docket and outcomes
- Generic filings/approvals in major markets
- Net-to-gross and rebate trends
Research AZN elsewhere
Keep the research going
More Rankings & Systems
Quality Stocks
High quality stocks ranked by profitability, margins, free cash flow quality, durability, solvency, and accounting...
Stock rankingUndervalued Stocks
Undervalued stocks from the NA & Europe universe, ranked with a multi-measure value system and quality controls.
Stock rankingDividend Stocks
Dividend stocks ranked by payout yield, payout sustainability, dividend growth, quality, balance-sheet safety, risk...
Stock rankingDefensive Stocks
Defensive stocks ranked by low volatility, low beta, intermediate momentum, durable profitability, balance sheet...
Stock rankingMomentum Stocks
Momentum stocks ranked by total return momentum, relative momentum, trend confirmation, and risk-adjusted momentum...
Stock rankingConviction 10
A concentrated 10-stock strategy from the NA & Europe universe, ranked across quality, value, growth, momentum, and...
Curation & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.